AtriCure, Inc. Appoints Deborah H. Telman to its Board of Directors

by savoystaff

AtriCure, Inc., a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced that Deborah H. Telman has been elected to its Board of Directors.

Ms. Telman has spent over 20 years in senior executive roles at global companies. She is Executive Vice President and General Counsel for Organon (NYSE: OGN), a global healthcare company formed in June 2021 through a spinoff from Merck (NYSE: MRK) (known as MSD outside of the United States and Canada) to focus on improving the health of women throughout their lives. Ms. Telman helped lead the separation work that created a standalone company serving more than 140 markets with more than 60 medicines and products across a range of therapeutic areas. Going forward she has responsibility for the company’s worldwide legal affairs, compliance, and global environmental health and safety. Before Organon, Ms. Telman was General Counsel at Sorrento Therapeutics (Nasdaq: SRNE), where she was responsible for mergers and acquisitions, licensing, governance, finance, human resources, regulatory compliance, and legal functions. Previously, she spent four years at Johnson Controls International plc (NYSE: JCI) as Vice President and General Counsel – Building Solutions, North America, and prior to that she held executive roles at Abbott Laboratories (NYSE: ABT) and The Boeing Company (NYSE: BA), and was a partner at Winston and Strawn LLP.

“I’m looking forward to joining the board of AtriCure and working with Mike and the rest of the management team to further the company’s mission,” said Ms. Telman. “There is an incredible opportunity to treat more patients with innovative therapies and the company has many catalysts for continued growth.”

“I am thrilled that Deb has agreed to join the AtriCure Board of Directors,” said Michael Carrel, President and Chief Executive Officer. “She has been a part of some incredible companies and have experience in leading by building scale through periods of significant growth. Deb’s expertise in financial matters, compliance, regulatory, legal, commercial initiatives, and corporate strategy will be additive to our company and our team.”


0 comment

You may also like